Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study

@inproceedings{Alam2014SafetyTA,
  title={Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study},
  author={Mohammed Y. Alam and Paula L Jacobsen and Yinzhong Chen and Michael Serenko and Atul R. Mahableshwarkar},
  booktitle={International clinical psychopharmacology},
  year={2014}
}
Patients with major depressive disorder often experience relapse after responding to treatment; therefore, maintenance therapy with antidepressants is recommended for maintaining response or remission. This multicenter, open-label, flexible-dose, 52-week extension study evaluated the long-term safety, tolerability, and maintenance of efficacy in study participants who had completed one of two randomized, double-blind, placebo-controlled, 8-week dose-ranging vortioxetine trials in study… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 26 CITATIONS

Effectiveness of long-term vortioxetine treatment of patients with major depressive disorder

  • European Neuropsychopharmacology
  • 2017
VIEW 6 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Vortioxetine: a review of its use in major depressive disorder.

VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Vortioxetine: First Global Approval

VIEW 8 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 28 REFERENCES

Antidepressants and body weight: a comprehensive review and meta-analysis.

  • The Journal of clinical psychiatry
  • 2010
VIEW 2 EXCERPTS
HIGHLY INFLUENTIAL

Escitalopram in the long-term treatment of major depressive disorder.

  • Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists
  • 2006
VIEW 1 EXCERPT
HIGHLY INFLUENTIAL

Practice guideline for the treatment of patients with major depressive disorder, 3rd ed

National Guideline Clearinghouse
  • Agency for Healthcare Research and Quality (AHRQ). Available at: http://www.guideline.gov/ content.aspx?id = 24158. [Accessed 15 March 2013].
  • 2013
VIEW 2 EXCERPTS

Similar Papers

Loading similar papers…